Evidence map›Paper›PMID 37184631›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.

R Paczkowski, J L Poon, K N Cutts, N Krucien, B Osumili, C Piras de Oliveira, E R Hankosky, M Perez-Nieves, C Radawski, H L Gelhorn

Open access · goldAbstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Perspectives and Preferences of People with Type 2 Diabetes for the Attributes of Weekly Insulin.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

R PaczkowskiEli Lilly and Company, Indianapolis, IN, USA.
J L PoonEli Lilly and Company, Indianapolis, IN, USA.
K N CuttsEvidera, Patient-Centered Research, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA.
N KrucienEvidera, Patient-Centered Research, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA.
B OsumiliEli Lilly and Company Ltd, Bracknell, UK.
C Piras de OliveiraEli Lilly and Company, Indianapolis, IN, USA.
E R HankoskyEli Lilly and Company, Indianapolis, IN, USA.
M Perez-NievesEli Lilly and Company, Indianapolis, IN, USA.
C RadawskiEli Lilly and Company, Indianapolis, IN, USA.
H L GelhornEvidera, Patient-Centered Research, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, 20814, USA. healther.gelhorn@evidera.com.
Eli Lilly (United States) · USGramercy Research Group (United States) · USEli Lilly (United Kingdom) · GBIthaka Harbors · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile there have been continued advances in insulin treatment for diabetes since the discovery of insulin 100 years ago, some unmet needs still remain, including those related to mealtime insulin (MTI). The objective of this study was to explore the impacts related to MTI and the relative burden of the impacts on people with diabetes.

methodsThis study was conducted across two phases, namely, a qualitative and quantitative phase. People with type 1 and 2 diabetes using MTI in the USA and UK were recruited for the study. The qualitative phase involved 30 interviews to explore the impacts associated with MTI. Based on the results of the qualitative phase, a list of impacts was developed to evaluate the importance of MTI impacts using best-worst scaling.

resultsA total of 30 participants completed interviews, and 336 completed the quantitative phase. Participants described a range of impacts associated with MTI, including psychological (72.0%), social (63.0%), work/school (53.8%), and sleep (51.7%). Impacts for the quantitative phase were categorized under the following domains: diabetes distress, diabetes management, work productivity, and social. The three most burdensome impacts were related to diabetes distress, but the diabetes management domain contributed more than diabetes distress to the relative burden. There were minor differences in the relative importance of impacts by diabetes type, diabetes duration, and experience with continuous glucose monitoring.

conclusionThis study confirms that people with diabetes using MTI still have an array of unmet needs, including those related to the management of their diabetes and the emotional distress of having diabetes. These findings may be useful for healthcare provider (HCP)-patient interactions to ensure HCPs are allowing patients an opportunity to discuss their experiences with MTI.

Indexed as

Best—worst scalingDiabetesImpactsMealtime insulinPatient experienceUnmet needs

Identifiers

PMID37184631
PMCPMC10184069
OpenAlexW4376609562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.